Form 4: Zenas BioPharma Director Boosts Stake with $6M Stock Buy

Zenas BioPharma Director Hongbo Lu, through affiliated entities, reported significant indirect purchases of common stock totaling 321,983 shares across two transactions.

Summary

• Hongbo Lu, a Director and 10% Owner of Zenas BioPharma, Inc. (ZBIO), reported indirect acquisitions of common stock.
• On September 13, 2024, 58,823 shares were acquired at $17 per share, totaling $1,000,000.
• On October 7, 2025, an additional 263,160 shares were acquired at $19 per share, totaling $5,000,040.
• Following these transactions, the total indirect beneficial ownership attributed to Hongbo Lu is 321,983 shares.
• The shares are held through NEXTBio Master Fund LP and NextBio Evergreen LLC, with Hongbo Lu being a managing member of the general partners/managing members of these entities.
• Hongbo Lu disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein.

Sentiment

Score: 8

Explanation: The significant indirect purchases by a Director and 10% Owner, totaling over $6 million, indicate strong insider confidence in the company's future, which is a highly positive signal for investors.

Positives

• A Director and 10% Owner, Hongbo Lu, increased their indirect stake in Zenas BioPharma, Inc. by a significant amount, signaling confidence in the company's future.
• The total value of the acquired shares across both transactions is $6,000,040.
• The second transaction on October 7, 2025, involved a higher price per share ($19) compared to the first ($17), suggesting continued belief in the company's value even at a higher valuation.

Risks

• The reporting person, Hongbo Lu, disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest, which is a standard legal disclaimer but highlights the indirect nature of the ownership through investment funds.

Future Outlook

This Form 4 filing does not contain explicit forward-looking statements or guidance from the company, but insider buying can implicitly signal a positive outlook from the reporting person.

Management Comments

• The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by NEXTBio Capital LLC, NEXTBio Capital Management LP, and Hongbo Lu, a managing member of NEXTBio Capital LLC.
• The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

Insider buying, especially by a director and significant owner, is often interpreted by the market as a strong signal of confidence in the company's future prospects and intrinsic value, potentially indicating that the insider believes the stock is undervalued. This can be particularly impactful in the biotechnology sector where future success often hinges on clinical trial outcomes and regulatory approvals.

Comparison to Industry Standards

• A Form 4 filing reports individual insider transactions and does not typically provide data for direct comparison to industry-wide benchmarks or specific competitor results. The significance lies in the insider's conviction rather than comparative performance metrics.

Related Party Transactions

• The transactions involve indirect ownership through investment funds (NEXTBio Master Fund LP and NextBio Evergreen LLC) where Hongbo Lu holds managing member positions, indicating related party dealings in the acquisition of shares.

Stakeholder Impact

• Shareholders may view this significant insider buying as a positive indicator of management's belief in the company's value and future performance, potentially boosting investor confidence.

Key Dates

Recommendation

The significant indirect purchases by Director and 10% Owner Hongbo Lu, totaling over $6 million, signal strong insider confidence in Zenas BioPharma's future prospects. Such substantial insider buying, particularly at increasing price points, often suggests that management believes the stock is undervalued or anticipates positive developments, making it a compelling 'buy' signal for investors.

Keywords

Zenas BioPharma, ZBIO, Form 4, insider buying, beneficial ownership, director stock purchase, equity acquisition, NEXTBio Master Fund, NextBio Evergreen